Compare KR & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KR | RMD |
|---|---|---|
| Founded | 1883 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 33.6B |
| IPO Year | 2007 | 1996 |
| Metric | KR | RMD |
|---|---|---|
| Price | $69.27 | $233.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 20 |
| Target Price | $69.00 | ★ $265.11 |
| AVG Volume (30 Days) | ★ 6.7M | 1.3M |
| Earning Date | 12-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.26% | 1.10% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | 2.51 | ★ 2.92 |
| Revenue | ★ $147,642,000,000.00 | $2,957,013,000.00 |
| Revenue This Year | $2.12 | $3.23 |
| Revenue Next Year | $1.59 | $6.40 |
| P/E Ratio | ★ $27.48 | $82.37 |
| Revenue Growth | 0.35 | ★ 13.44 |
| 52 Week Low | $54.15 | $180.27 |
| 52 Week High | $76.58 | $277.67 |
| Indicator | KR | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.23 | 52.73 |
| Support Level | $65.34 | $217.41 |
| Resistance Level | $72.45 | $242.40 |
| Average True Range (ATR) | 1.66 | 7.05 |
| MACD | 0.23 | -2.00 |
| Stochastic Oscillator | 93.90 | 55.69 |
Founded in 1883, Kroger is the largest pure-play supermarket operator in the United States, operating roughly 2,700 stores across more than 30 banners. Kroger's business is primarily grocery-led (roughly 79% of sales), spanning fresh food and private-label offerings, complemented by fuel centers (9%) and pharmacies (12%). The firm also generates income from advertising, data analytics, and manufacturing.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.